CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

RevMed could become ‘next oncology titan’ with Rasonque nod

RasonquePositive
AI Analysis

Summary

Truist Securities projects that an expansion of Rasonque into first-line pancreatic ductal adenocarcinoma could enable Revolution Medicines to achieve $2.3 billion in sales by 2028, positioning the company as a potential oncology leader.

Financial Highlights

Revenue

$2.3 billion

Guidance

2028 sales projection

Importance:4/10
Sentiment:
0.70
oncologypancreatic cancersales projectionexpansion
Related Companies

Read the original article

Published by BioSpace on August 27, 2026 11:39 AM

Read Original